United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium
Clinical Gastroenterology and Hepatology · 2026-05
DOI: 10.1016/j.cgh.2026.04.025 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Kavish R Patidar und 47 weiteren Autor:innen. Beteiligte Einrichtung: Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C. Walter Jr Transplant Center, Houston Methodist Hospital, Houston, Texas. Hauptthemen laut MEDLINE: Terlipressin, Hepatorenal Syndrome, Liver Transplantation, Vasoconstrictor Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND & AIMS: Terlipressin became the first United States Food and Drug Administration-approved therapy for hepatorenal syndrome-acute kidney injury in 2022. We present its initial experience at 16 United States academic medical centers. METHODS: Consecutive patients with hepatorenal syndrome-acute kidney injury treated with terlipressin were followed for 90 days. Patients met standard criteria (conforming to United States Food and Drug Administration labeling guidance) or extended criteria (presence of ≥1 United States Food and Drug Administration warning/limitation: acute-on-chronic liver failure grade 3, serum creatinine >5 mg/dL, or hypoxia at initiation). Primary outcomes were overall response (complete or partial response per guidelines) and hepatorenal syndrome reversal (terminal serum creatinine
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C. Walter Jr Transplant Center, Houston Methodist Hospital, Houston, Texas.
- Center for Liver Disease and Transplantation, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
- Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.
- Division of Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico.
- Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- American Association for the Study of Liver Diseases
- Mallinckrodt Pharmaceuticals Canada
- W. L. Gore and Associates
Zitieren
APA
Patidar, K. R., Cullaro, G., Orman, E. S., Teixeira, J. P., Neyra, J. A., Robinson, J. E., Kapoor, A., Simonetto, D. A., Gonzalez, S. A., Asrani, S. K., Vargas, H. E., Rajan, A., Fricker, Z., Weinberg, E., Velez, J. C., Belcher, J. M., Wadei, H., Fortune, B., Frederick, R. T., …, & HRS-HARMONY Research Collaboration (2026). United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.025
Vancouver
Patidar KR, Cullaro G, Orman ES, Teixeira JP, Neyra JA, Robinson JE, et al. United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.025
BibTeX
@article{Patidar2026,
author = {Patidar, Kavish R and Cullaro, Giuseppe and Orman, Eric S and Teixeira, J Pedro and Neyra, Javier A and Robinson, Jevon E and Kapoor, Aanchal and Simonetto, Douglas A and Gonzalez, Stevan A and Asrani, Sumeet K and Vargas, Hugo E and Rajan, Anjana and Fricker, Zachary and Weinberg, Ethan and Velez, Juan Carlos and Belcher, Justin M and Wadei, Hani and Fortune, Brett and Frederick, R Todd and Mehkri, Omar and Dolan, Bridget and Pickett, Caleigh and Skvarce, Jeremy and Sachar, Saloni and Lindenmeyer, Christina and Ouyang, Tianqi and Ufere, Nneka and Li, Xing and Lopes, Lexie and St Hillien, Shelsea and Whittaker, Sydney and Kusztos, Victoria and Vellutini, Natalie and Vissa, Anand and Walker, Olivia C and Fischbach, Connor and Boike, Justin and Subocz, Madelyn and Aghayeva, Sevda and Skipper, Gavin and Marin, Luis Madera and Singh, Rohanit and Alhayani, Ibrahim and Zakour, George and Haddad, Walid and Mejia, Paola and Allegretti, Andrew S and HRS-HARMONY Research Collaboration, HRS-HARMONY Research Collaboration},
title = {United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.025}
}
EUVIMED